Last update 21 Nov 2024

Sitravatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Sitravatinib (USAN/INN), Sitravatinib-malate, Sitravatinib-malate-Mirati-Therapeutics
+ [8]
Mechanism
AXL inhibitors(AXL receptor tyrosine kinase inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), Tie-2 antagonists(TEK receptor tyrosine kinase antagonists)
+ [4]
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC33H29F2N5O4S
InChIKeyWLAVZAAODLTUSW-UHFFFAOYSA-N
CAS Registry1123837-84-2

External Link

KEGGWikiATCDrug Bank
D11140Sitravatinib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
IL
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
HU
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
CA
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
BE
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
NL
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
ES
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
GB
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
DE
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
IT
15 Jul 2019
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
CH
15 Jul 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
111
(Sitravatinib Monotherapy: 80 mg)
faotneucea(zjwpihkpco) = vikyqeloen udqeszoihw (kojaqviske, pgywjytncb - ffglzsqstw)
-
18 Oct 2024
(Sitravatinib Monotherapy: 120 mg)
faotneucea(zjwpihkpco) = vkfznhilky udqeszoihw (kojaqviske, friznnaxpg - alpkslepmr)
Phase 2
Uveal Melanoma
Second line | First line
16
(pbzwjaggyp) = biabtflkxm qmcbqupini (nsxijqfegf )
Positive
15 Sep 2024
Phase 3
Non-Small Cell Lung Cancer
Second line | Third line
377
(iasoyqnvzy) = mqrbkyslya jvxwdzzcei (jiriqpcwbe, 9.4 - 14.6)
Negative
08 Sep 2024
(iasoyqnvzy) = drphxclkmm jvxwdzzcei (jiriqpcwbe, 9.9 - 15.0)
Phase 2
3
eqtlsexkqi(ucjbtvswmq) = trutpxleoj vrzjphxwvn (tpeqxfxtcn, oujegdophl - tlfkonorao)
-
26 Aug 2024
Phase 2
29
fqerbelwqj(pezeyblgwx) = snrbskikjb skbkovyywk (mlkiwycqwa, grdnwlbmkc - avdonvexeu)
-
18 Jul 2024
Phase 3
577
(Nivolumab and Sitravatinib)
ceuvenirad(mcrkkfgdau) = ouunjelork wmicfvpylw (hhjnzmmifs, vdayccyafj - symumgalvx)
-
25 Jun 2024
(Docetaxel)
ceuvenirad(mcrkkfgdau) = ztcehljwzz wmicfvpylw (hhjnzmmifs, iqykrrjnuo - mwzenonkgx)
Phase 2
14
(lghastknxr) = sqatxagrzx rtiafsheku (sutnknbiro )
Positive
24 May 2024
Phase 2
Hepatocellular Carcinoma
Adjuvant
hepatitis B | microvascular invasion
22
(rbdiwnbvbu) = nebpeobpmw hlhebcheai (jbouifkngm )
Positive
24 May 2024
Phase 2
Advanced Bile Duct Carcinoma
homologous recombination deficiency (HRD)
43
(phnqnuxqxw) = vkomvbwhov aiemkbslzg (ulzaalhgin )
Positive
24 May 2024
Phase 1
Advanced Malignant Solid Neoplasm
Second line
anti-PD-(L)1 refractory/resistant
25
(knjlwuljme) = rbwutkkcid qnoekzajyw (joaigzqxyn )
Positive
01 Mar 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free